Jupiter Neurosciences, Inc. Announces Reverse Stock Split
Rhea-AI Summary
Jupiter Neurosciences (NASDAQ: JUNS) approved a 1-for-75 reverse stock split of its common stock, authorized by shareholders on July 22, 2026. The reverse split becomes legally effective at 4:01 p.m. ET on August 6, 2026, with post-split trading on Nasdaq under the existing symbol JUNS and new CUSIP 48208B 302 starting August 7, 2026.
The move is intended to increase the per-share trading price and help regain compliance with Nasdaq’s minimum bid requirement. Outstanding shares will be reduced from approximately 57,756,143 to about 770,081, while authorized shares remain unchanged. No fractional shares will be issued; holders instead receive cash in lieu of fractional entitlements.
Positive
- 1-for-75 reverse split approved and fully scheduled for August 6–7, 2026
- Outstanding shares cut from ~57.76 million to ~770,081 post-split
- Reverse split aimed to support Nasdaq minimum bid price compliance
Negative
- 1-for-75 reverse split reflects a very large share consolidation
- Authorized share count unchanged despite significantly fewer shares outstanding
News Explained
The split also proportionally adjusts exercise and conversion prices and incentive-plan share counts; as a consolidation, the split itself does not change company value.
Market reaction after 1-for-75 reverse stock split: JUNS -22.20%
Following this news, JUNS has declined 22.20%, reflecting a significant negative market reaction. Argus tracked a trough of -14.5% from its starting point during tracking. Our momentum scanner has triggered 23 alerts so far, indicating elevated trading interest and price volatility. The stock is currently trading at $0.08.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jul 21 | License agreement | Positive | +2.9% | Exclusive U.S. ALA-002 rights; transaction valued at up to $100 million. |
| Jul 07 | Board appointment | Positive | -2.4% | Director appointment added Audit and Compensation Committee participation. |
| May 27 | Clinical enrollment | Positive | +4.3% | Phase 2a RESET enrollment began for a 30-patient Parkinson’s study. |
| May 21 | Registered offering | Negative | -12.2% | Registered direct offering closed with $2.0 million in gross proceeds. |
| May 20 | Offering pricing | Negative | -35.9% | Registered direct offering priced 7,142,858 common shares. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
JUNS historically aligned with the direction of four of five selected news reactions, with one positive announcement followed by a negative reaction.
Key Terms
reverse stock split financial
cusip number technical
book-entry form financial
convertible securities financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
Jupiter’s common stock is expected to begin trading on a post-split adjusted basis on August 7, 2026
JUPITER, FL, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) ("Jupiter" or the "Company"), a clinical-stage biopharmaceutical company focused on developing innovative therapies for neurological and neurodegenerative disorders, today announced that the board of directors of the Company approved a 1-for-75 reverse stock split (the “Reverse Split”) of the Company’s common stock. The Reverse Split was approved by the stockholders at the Company’s annual meeting of the stockholders held on July 22, 2026. The Reverse Split will legally take effect at 4:01 p.m. Eastern Time, on August 6, 2026. The Company’s common stock will open for trading under a new CUSIP number 48208B 302 on The Nasdaq Capital Market on August 7, 2026, on a split-adjusted basis under the current ticker symbol “JUNS.” The Reverse Split is intended to increase the per share trading price of the Company’s common stock to enable the Company to regain compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market.
The 1-for-75 Reverse Split will automatically convert every seventy-five (75) current shares of the Company’s common stock into one (1) share of common stock. No fractional shares will be issued in connection with the Reverse Split. Stockholders who would otherwise hold a fractional share of the Company’s common stock following the Reverse Split will receive a cash payment in lieu thereof equal to the fractional share to which the stockholder would otherwise be entitled multiplied by the closing sales price of a share of the Company’s common stock on The Nasdaq Capital Market, as adjusted for the Reverse Split, on the trading day immediately prior to the effective date of the Reverse Split, August 6, 2026.
The Reverse Split will reduce the number of shares of outstanding common stock from approximately 57,756,143 shares, the number of shares outstanding as of August 4, 2026, to approximately 770,081 shares. The total authorized number of shares will not be reduced. Proportional adjustments will also be made to the exercise and conversion prices of the Company’s outstanding stock options and convertible securities, and to the number of shares issued and issuable under the Company’s stock incentive plans.
Stockholders holding their shares electronically in book-entry form are not required to take any action to receive post-split shares. Stockholders owning shares through a bank, broker, or other nominee will have their positions automatically adjusted to reflect the Reverse Split, subject to brokers’ particular processes, and will not be required to take any action in connection with the Reverse Split. For those stockholders holding physical stock certificates, the Company’s transfer agent, Equiniti Trust Company, LLC, will send instructions for exchanging those certificates for shares held electronically in book-entry form or for new certificates, in either case representing the post-split number of shares, and any payments in cash in lieu of fractional shares, if applicable.
About Jupiter Neurosciences, Inc.
Jupiter Neurosciences, Inc. (NASDAQ: JUNS) is a clinical-stage biopharmaceutical company advancing a therapeutic pipeline targeting central nervous system disorders and neuroinflammation. The Company’s present lead program, JOTROL™ — a proprietary, enhanced-bioavailability resveratrol formulation — is currently in a Phase IIa clinical trial for Parkinson’s disease. JUNS also commercializes Nugevia™, a consumer longevity supplement. The acquisition of exclusive U.S. rights to ALA-002 further strengthens the Company’s CNS pipeline by adding a next-generation, patented psychedelic NCE at a pivotal moment in U.S. regulatory policy. For more information, visit www.jupiterneurosciences.com.
Forward Looking Statements
Any statements in this press release about our future expectations, plans and prospects, including statements regarding our strategy, future operations, prospects, plans and objectives, the timing and effectiveness of the Reverse Split, the Company’s ability to regain compliance with the Nasdaq minimum bid price and other listing requirement and other statements containing the words "believes," "anticipates," "plans," "expects," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including statements regarding the Company’s current objectives. These statements are based on the Company's current expectations and beliefs and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law. Additional information regarding these and other risks and uncertainties is contained in the Company's filings with the Securities and Exchange Commission, including the Company's most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q.
INVESTOR & MEDIA CONTACT
Company: Jupiter Neurosciences, Inc.
Address: 11621 Kew Gardens Ave, Suite 210, Jupiter, FL 33410
Phone: +1 (561) 406-6154
Investor Relations: ir@jupiterneurosciences.com
